This was the stock's third consecutive day of losses.

AbbVie Inc (ABBV) stock saw a decline, ending the day at $179.53 which represents a decrease of $-0.57 or -0.32% from the prior close of $180.1. The stock opened at $179.63 and touched a low of ...

This was the stock's second consecutive day of losses.

BofA Securities has recently resumed AbbVie Inc (ABBV) stock to Neutral rating, as announced on December 10, 2024, according to Finviz. Earlier, on December 5, 2024, Daiwa Securities had reduced the ...

DCF analysis, a reliable and data-driven approach to estimating its intrinsic value. Instead of using future free cash flow ...

We recently compiled a list of the 13 Best Pharma Dividend Stocks To Buy In 2024. In this article, we are going to take a ...

Boltwood Capital Management decreased its position in AbbVie Inc. (NYSE:ABBV – Free Report) by 1.4% in the 4th quarter, ...

Gene therapy firm Capsida Biotherapeutics is advancing the first of its AbbVie-partnered neurodegenerative disease therapies ...

If you want to know who really controls AbbVie Inc. ( NYSE:ABBV ), then you'll have to look at the makeup of its share ...

We recently compiled a list of the 10 Best Dividend Growth Stocks to Buy and Hold in 2025. In this article, we are going to ...

Truist Financial analyst Srikripa Devarakonda maintained a Buy rating on AbbVie (ABBV – Research Report) yesterday and set a price target of ...

CWA Asset Management Group LLC cut its holdings in AbbVie Inc. (NYSE:ABBV – Free Report) by 13.1% in the 4th quarter, ...